ACT for CP Individual Patient Expanded Access IND Protocol
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03203941
Expanded Access Status :
No longer available
First Posted : June 29, 2017
Last Update Posted : March 1, 2019
Information provided by (Responsible Party):
Charles Cox, The University of Texas Health Science Center, Houston
Individual patient expanded access protocol for a child with cerebral palsy (CP) who has autologous umbilical cord blood available and who is ineligible to participate in other stem cell studies for children with CP.
Condition or disease
Biological: Autologous Cord Blood Stem Cells
This protocol is part of an FDA Individual Patient Expanded Access IND submitted at the request of the parents of a child with cerebral palsy (CP) who is ineligible to participate in other stem cell studies. For this child, there are no other treatment options.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Charles Cox, The George and Cynthia Mitchell Distinguished Chair in Neurosciences Director, Children's Program in Regenerative Medicine Professor, Department of Pediatric Surgery UTHealth McGovern Medical School at Houston, The University of Texas Health Science Center, Houston